This study tests a medicine called **cemiplimab** for treating a type of skin cancer called **cutaneous squamous cell cancer (cSCC)**. The medicine works with your immune system to help fight cancer. Patients will receive cemiplimab before and after surgery to see if it helps prevent the cancer from coming back. **Key points:** - **Study Duration**: The study involves taking cemiplimab every 21 days. Before surgery, patients receive up to 3 cycles; after surgery, up to 18 cycles. - **Follow-Up**: After treatment, patients will have check-ups every 12 weeks for 2 years, then every 6 months for 3 years, and annually for up to 10 years. - **Eligibility**: Participants need a certain type of high-risk cSCC, must be able to have surgery, and meet specific health criteria. Note: Women who could become pregnant must have a negative pregnancy test and agree to use birth control, and participants should not donate blood or reproductive cells during the study. If you're interested, talk to your doctor to see if you qualify.